Cetrorelix vs Bremelanotide
Head-to-head comparison of Cetrorelix (Cetrorelix acetate) and Bremelanotide (Bremelanotide (PT-141), cyclic melanocortin receptor agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cetrorelix | Bremelanotide |
|---|---|---|
| Category | Sexual Health | Sexual Health |
| Full Name | Cetrorelix acetate | Bremelanotide (PT-141), cyclic melanocortin receptor agonist |
| Molecular Weight | 1431.06 Da | 1025.2 Da |
| Half-Life | ~30 hours | about 2.7 h |
| Amino Acids | 10 | 7 |
| Typical Dose | 0.25 mg SC daily | 1.75 mg |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 300 | 200 |
| Research Status | Clinical | Clinical |
Cetrorelix Benefits
- ✓prevents premature ovulation
- ✓supports IVF cycle control
- ✓blocks LH surge
- ✓short-acting pituitary suppression
Bremelanotide Benefits
- ✓increases sexual desire
- ✓supports arousal
- ✓may improve erectile response
- ✓on-demand use
Cetrorelix Dosing
0.25 mg SC daily|start on stimulation day 5-6|protocol-dependent antagonist cycle
Bremelanotide Dosing
1.75 mg subcutaneous PRN|administer about 45 minutes before activity|max 1 dose per 24 hours
Cetrorelix Side Effects
- ⚠injection-site reactions
- ⚠headache
- ⚠nausea
Bremelanotide Side Effects
- ⚠nausea
- ⚠flushing
- ⚠headache
- ⚠transient blood pressure increase
Research Overview
Cetrorelix
Cetrorelix is a cornerstone GnRH antagonist in assisted reproduction, with a fast onset and reversible suppression of LH. Trials show it improves cycle management by reducing premature ovulation during stimulation.
Bremelanotide
Human studies and approval data support meaningful effects on sexual desire in women, with a central mechanism involving melanocortin signaling. It is one of the most clinically relevant peptides in this category and is commonly used as the reference compound for PT-141-type research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.